Xention Limited Strengthens Team with New Director of Business Development
Xention Ltd announced the appointment of Dr Calum Graham as Director of business development. Dr Graham is an experienced business development executive with a strong scientific background and expert knowledge of the drug development process gained over nineteen years in the pharmaceutical industry. He joins Xention from GlaxoSmithKline, where he held the position of Director of Scientific Licensing in Worldwide Business Development for the last six years.
While at GSK, Dr Graham was responsible for business development and licensing within the neurosciences therapeutic area. He led the evaluation of numerous licensing and acquisition opportunities, including completion of over twenty-five due diligences and the successful completion of numerous, substantial deals. Prior to this, he held senior roles in a number of other departments within GSK including Head of Disease Strategy in the Neurology & GI Centre of Excellence for Drug Discovery (CEDD) and Assistant Director in the Anti-Infective Therapeutic Unit. He holds a PhD in Pharmacology from the University of Dundee.
Other news from the department people
